Drug intelligence / Profile preview

SPVX03

Development stage: Discontinued
Lead developer: Stablepharma
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SPVX03 is a discontinued, preclinical-stage thermostable vaccine candidate developed by Stablepharma for the prevention of tetanus and diphtheria (Td). The vaccine was designed using Stablepharma's proprietary StablevaX™ technology, which reformulates vaccines into a fridge-free, dry format to eliminate the need for cold-chain storage and transport. SPVX03 was formulated for administration via a specialized syringe delivery system.

Targets

Diphtheria toxoid-specific B-cell receptor

Beyond the preview

Go deeper on SPVX03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPVX03.

Explore the full profile